Trial Profile
A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period and a Long- Term Extension Period to Evaluate the Efficacy and Safety of LY2439821 in Patients With Moderate-to-Severe Plaque Psoriasis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 15 May 2023
Price :
$35 *
At a glance
- Drugs Ixekizumab (Primary)
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Acronyms UNCOVER-1
- Sponsors Eli Lilly and Company
- 21 Mar 2023 Results of post-hoc pooled analysis assessing patient-reported fatigue, using the SF-36 vitality domain, in patients who received ixekizumab 80 mg Q2W for 12 weeks for moderate-to-severe psoriasis across UNCOVER-1 (N=433), UNCOVER-2 (N=351), UNCOVER-3 (N=385), and IXORA-S (N=136) SPIRIT-H2H presented at the American Academy of Dermatology annual Meeting 2023
- 21 Mar 2023 Results of post-hoc pooled analysis assessing the disease improvement and clearance of palmoplantar PsO in the palms and soles of patients with moderate-to-severe plaque PsO and baseline palmoplantar PsO who were treated with ixekizumab for up to 5 years across 6 clinical trials (NCT01474512, NCT01597245, NCT01646177, NCT03364309, NCT02561806 and NCT03073200), presented at the American Academy of Dermatology annual Meeting 2023.
- 25 Apr 2021 Results assessing effects of baseline psoriatic arthritis on IXE efficacy and safety in moderate to severe psoriasis patients over 5 years from UNCOVER clinical trials (UNCOVER 1, 2 and 3) presented at the American Academy of Dermatology Virtual Meeting Experience 2021